Eyenovia, Inc. Prices Public Offering of Common Stock
August 19 2020 - 9:10AM
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose array
print (MAP™) therapeutics, today announced the pricing of an
underwritten public offering of 3,333,334 shares of its common
stock at a price to the public of $3.60 per share. In addition,
Eyenovia has granted the underwriters a 30-day option to purchase
up to 500,000 additional shares of common stock at the public
offering price, less underwriting discounts and commissions. The
offering is expected to close on August 21, 2020, subject to
customary closing conditions.
The gross proceeds to Eyenovia from the public offering, before
deducting underwriting discounts and commissions and offering
expenses payable by Eyenovia, are expected to be approximately $12
million. Eyenovia intends to use the net proceeds from the public
offering, together with existing funds, to fund the continued
clinical development of its product candidates, initial
commercialization activities for MicroStat, and for working capital
and general corporate purposes.
William Blair & Company, L.L.C. is acting as sole
book-running manager for the offering. National Securities
Corporation is acting as the co-manager for the offering.
The offering is being made pursuant to a shelf registration
statement on Form S-3 (File No. 333-229365) that was declared
effective by the Securities and Exchange Commission (the “SEC”) on
February 12, 2019. A preliminary prospectus supplement related to
the offering has been filed with the SEC and a final prospectus
supplement with the final terms of the offering will be filed with
the SEC and will be available on the SEC’s website, located at
www.sec.gov. Copies of the prospectus supplement and the
accompanying prospectus relating to the offering may also be
obtained from William Blair & Company, L.L.C., Attention:
Prospectus Department, 150 North Riverside Plaza, Chicago, IL
60606, or by calling (800) 621-0687, or emailing
prospectus@williamblair.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any offer or sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction. Any offer, if at all, will be made only
by means of a prospectus supplement and accompanying prospectus,
which are a part of the effective registration statement.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose array
print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused
on the late-stage development of microdosed medications for
presbyopia, myopia progression and mydriasis. For more Information,
please visit www.eyenovia.com.
Forward-Looking Statements
Except for historical information, all of the statements,
expectations, and assumptions contained in this press release are
forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions or any
other statements relating to our future activities or other future
events or conditions. These statements are based on current
expectations, estimates and projections about our business based,
in part, on assumptions made by management. These statements are
not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and are likely to,
differ materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors discussed from
time to time in documents which we file with the SEC. In addition,
such statements could be affected by risks and uncertainties
related to, among other things, the Company’s expectations
regarding the closing of the public offering, its anticipated use
of net proceeds from the public offering, its need to raise
additional capital even after this financing, and other risks and
uncertainties described in Eyenovia’s filings with the SEC. Any
forward-looking statements speak only as of the date on which they
are made, and except as may be required under applicable securities
laws, Eyenovia does not undertake any obligation to update any
forward-looking statements.
Company Contact:Eyenovia, Inc.John
GandolfoChief Financial Officerjgandolfo@eyenoviabio.com
Investor Contact:The Ruth GroupAlexander
LoboPhone: 646-536-7037alobo@theruthgroup.com
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Apr 2023 to Apr 2024